Minodronic acid
|
|
|
- CAS-Nr.
- 180064-38-4
- Englisch Name:
- Minodronic acid
- Synonyma:
- BPH 261;Bonoteo;Recalbon;ONO 5920;Nsc725590;Minodronicaci;Mino phosphate;Minodronic Acid;Minodronic acid (anhydrous);(127657-42-5) minodronic acid
- CBNumber:
- CB41011573
- Summenformel:
- C9H12N2O7P2
- Molgewicht:
- 322.15
- MOL-Datei:
- 180064-38-4.mol
|
Minodronic acid Eigenschaften
- Dichte
- 1.97±0.1 g/cm3(Predicted)
- storage temp.
- under inert gas (nitrogen or Argon) at 2-8°C
- Löslichkeit
- Aqueous Base (Slightly), Methanol (Slightly)
- Aggregatzustand
- Solid
- pka
- 1.48±0.10(Predicted)
- Farbe
- White to Off-White
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitsschädlich bei Verschlucken. |
Akute Toxizität oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
|
| Sicherheit |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen. |
|
Minodronic acid Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Minodronic acid hydrate, a third-generation bisphosphonate, was
approved and launched in Japan for the oral treatment of
osteoporosis. Osteoporosis is a skeletal disorder characterized by low bone mass and structural deterioration of bone tissue resulting in bone
fragility and increased susceptibility to fractures, particularly of the hip,
spine, and wrist. It is the most common type of metabolic bone disease
and a major health concern affecting 200 million women worldwide.
Minodronic acid is the newest nitrogen-containing bisphosphonate to reach the market. In vitro, it inhibits
recombinant human FPP synthase activity with similar potency as zoledronic acid (IC
50 = 3 nM for both agents).
The most common adverse events associated with minodronic acid included stomach and abdominal discomfort, abdominal pain, decrease in blood calcium level, and gastritis. The chemical synthesis of minodronic acid starts with a condensation reaction of 2-aminopyridine with ethyl 4-bromo-3-oxobutyrate by means of sodium bicarbonate to produce 2-(imidazo[1,2-a]pyridin-3-yl)acetic acid ethyl ester, which is hydrolyzed to the corresponding carboxylic acid with potassium hydroxide. Treatment of the carboxylic acid intermediate with phosphorus acid and phosphorus trichloride followed by hydrolysis with hydrochloric acid gives minodronic acid.
Verwenden
Minodronic acid is developed for osteoporosis treatment.
Minodronic acid Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Minodronic acid Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 138)Lieferanten
180064-38-4()Verwandte Suche:
- PHOSPHONIC ACID, (1-HYDROXY-2-IMIDAZO(1,2-A)PYRIDIN-3-YLETHYLIDENE)BIS-
- 1-Hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bis(phosphonic acid)
- (1-Hydroxy-2-imidazo[1,2-A]pyridin-3-yl-1-ethyl)-1,1-bisphos phonate
- Nsc725590
- Bonoteo
- BPH 261
- ONO 5920
- Recalbon
- (1-Hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diyl)diphosphonic acid
- Phosphonic acid,P,P'-(1-hydroxy-2-iMidazo[1,2-a]pyridin-3-ylethylidene)bis-
- Minodronic acid (anhydrous)
- (127657-42-5) minodronic acid
- 1-Hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)-1,1-ethanediyl]bis(phosphonic acid)
- Minodronicaci
- PHOSPHONIC ACID, (1-HYDROXY-2-IMIDAZO(1,2-A)PYRIDIN-3-YLETHYLIDENE)BIS- ISO 9001：2015 REACH
- Minodronic Acid
- Mino phosphate
- 180064-38-4
- C9H12N2O7P2
- API
